Ex Vivo Apoptosis in CD8+ Lymphocytes Predicts Rectal Cancer Patient Outcome

Figure 3

Kaplan-Meier analysis of CD8+ apoptotic rates after 2 Gy (a) metastasis-free survival, (b) disease-free survival, 8 Gy, (c) metastasis-free survival, (d) disease-free survival and 2 Gy and 10 μg/mL Oxaliplatin, (e) metastasis-free survival, and (f) disease-free survival. values are calculated by the log-rank test. Numbers of patients at risk at the times of 0, 12, 24, and 36 months of follow-up and percentage of remaining patients with event-free survival are indicated.

(a)

(b)

(c)

(d)

(e)

(f)